5-Aminolevulinic Acid-Mediated Metronomic Photodynamic Therapy for Mouse Mammary Tumors
[ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells...
Saved in:
| Published in | YONAGO ACTA MEDICA Vol. 68; no. 2; pp. 114 - 122 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Tottori University Medical Press
2025
YAM |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0513-5710 1346-8049 1346-8049 |
| DOI | 10.33160/yam.2025.05.004 |
Cover
| Abstract | [ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT. [Methods] In an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm. [Results] In the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm. [Conclusion] Considering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration. |
|---|---|
| AbstractList | [ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT. [Methods] In an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm. [Results] In the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm. [Conclusion] Considering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration. Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT.BackgroundMetronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT.In an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm.MethodsIn an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm.In the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm.ResultsIn the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm.Considering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration.ConclusionConsidering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration. Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT. In an experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm. In the experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm were significantly higher than those of cells in the 620-nm group. In contrast, in the experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm. Considering the results of our study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration. |
| Author | Hideo Imazato Takahiro Nishimura Yutaka Miyazono Hikaru Shiomi Urara Ota Ryoichi Yamaguchi Katsuyuki Morii Kei Sakanoue Kiwamu Takahashi Tomohiro Osaki Katsuhiko Fujita Masahiro Ishizuka Tsuyoshi Goya Kazuhiro Eguchi Naoki Kobayashi Kenji Kuwata |
| Author_xml | – sequence: 1 givenname: Tomohiro surname: Osaki fullname: Osaki, Tomohiro organization: Joint Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan – sequence: 2 givenname: Hikaru surname: Shiomi fullname: Shiomi, Hikaru organization: Joint Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan – sequence: 3 givenname: Takahiro surname: Nishimura fullname: Nishimura, Takahiro organization: Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan – sequence: 4 givenname: Kei surname: Sakanoue fullname: Sakanoue, Kei organization: Pleiades Technologies LLC, Fukuoka 814-0001, Japan – sequence: 5 givenname: Kazuhiro surname: Eguchi fullname: Eguchi, Kazuhiro organization: Pleiades Technologies LLC, Fukuoka 814-0001, Japan – sequence: 6 givenname: Yutaka surname: Miyazono fullname: Miyazono, Yutaka organization: Pleiades Technologies LLC, Fukuoka 814-0001, Japan – sequence: 7 givenname: Ryoichi surname: Yamaguchi fullname: Yamaguchi, Ryoichi organization: Kumamoto Industrial Research Institute, Kumamoto 862-0901, Japan, ||Institute for Materials Chemistry and Engineering, Kyushu University, Fukuoka 816-8580, Japan – sequence: 8 givenname: Katsuhiko surname: Fujita fullname: Fujita, Katsuhiko organization: Institute for Materials Chemistry and Engineering, Kyushu University, Fukuoka 816-8580, Japan – sequence: 9 givenname: Kenji surname: Kuwata fullname: Kuwata, Kenji organization: NIPPON SHOKUBAI CO., LTD., Osaka 541-0043, Japan – sequence: 10 givenname: Naoki surname: Kobayashi fullname: Kobayashi, Naoki organization: NIPPON SHOKUBAI CO., LTD., Osaka 541-0043, Japan – sequence: 11 givenname: Tsuyoshi surname: Goya fullname: Goya, Tsuyoshi organization: NIPPON SHOKUBAI CO., LTD., Osaka 541-0043, Japan – sequence: 12 givenname: Katsuyuki surname: Morii fullname: Morii, Katsuyuki organization: Nippon Shokubai Research Alliance Laboratories Osaka University, Osaka 565-0871, Japan – sequence: 13 givenname: Urara surname: Ota fullname: Ota, Urara organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan – sequence: 14 givenname: Hideo surname: Imazato fullname: Imazato, Hideo organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan – sequence: 15 givenname: Kiwamu surname: Takahashi fullname: Takahashi, Kiwamu organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan – sequence: 16 givenname: Masahiro surname: Ishizuka fullname: Ishizuka, Masahiro organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40432740$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVUclu2zAUJIoEjeP23lOhYy9yH3f5VBhBmgSIkRwc9EhQ4lPMQCJdLSn096VqdwMeuGDmbTOX5CzEgIR8oLDinCr4PNl2xYDJFaQA8YYsKBcqL0Csz8gCJOW51BQuyGXfvyQCl6DekguRXkwLWJBvMt-0PsQGX8fGB19lm8q7fIvO2wFdtsWhiyG2CXjcxyG6Kdj5s9tjZw9TVscu28axx2xr29Z2U7Yb29j178h5bZse35_uJXn6er27us3vH27urjb3eSUViNxiKa1Ax7CoAWldq0LqWpU1cuvWomZVyTRypWstS6VZoR1LswNymqiO8iWhx7pjONjph20ac-j8PIihYH6JZJJIZhbJQIqUvSRfjjmHsWzRVRiGzv7Ni9ab_5Hg9-Y5vhrKKAipdarw6VShi99H7AfT-r7CprEBkxiGM8p0IcSaJerHf5v96fLbgkS4ORIS6ivbxJB8QPMSxy4k5YzzbIrBPp9WAFUAm9cwQOl8MCbk7PGa_wRjx6Ej |
| ContentType | Journal Article |
| Copyright | 2025 Tottori University Medical Press. 2025 Tottori University Medical Press 2025 |
| Copyright_xml | – notice: 2025 Tottori University Medical Press. – notice: 2025 Tottori University Medical Press 2025 |
| CorporateAuthor | Institute for Materials Chemistry and Engineering NIPPON SHOKUBAI CO Graduate School of Engineering Kumamoto Industrial Research Institute Kyushu University Pleiades Technologies LLC SBI Pharmaceuticals Co Faculty of Agriculture Tottori University Osaka University Joint Department of Veterinary Medicine LTD Nippon Shokubai Research Alliance Laboratories Osaka University |
| CorporateAuthor_xml | – name: Graduate School of Engineering – name: Nippon Shokubai Research Alliance Laboratories Osaka University – name: Kyushu University – name: NIPPON SHOKUBAI CO – name: Tottori University – name: LTD – name: Joint Department of Veterinary Medicine – name: Institute for Materials Chemistry and Engineering – name: Kumamoto Industrial Research Institute – name: Pleiades Technologies LLC – name: Osaka University – name: SBI Pharmaceuticals Co – name: Faculty of Agriculture |
| DBID | NPM 7X8 5PM ADTOC UNPAY |
| DOI | 10.33160/yam.2025.05.004 |
| DatabaseName | PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1346-8049 |
| EndPage | 122 |
| ExternalDocumentID | 10.33160/yam.2025.05.004 PMC12104577 40432740 di2yonag_2025_006802_004_0114_01224557109 |
| Genre | Journal Article |
| GroupedDBID | --- .55 .GJ 123 2WC 3O- 53G 7.U ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP C1A DIK E3Z EMOBN F5P FRP GX1 HYE JMI JSF JSH KQ8 MOJWN OK1 P2P RJT RPM RZJ TR2 W2D X7M NPM 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c5604-aeb5a4ed2e8f0e1ff6857f6bfe3ad94f2cb27e367f75b67287d20430e31f68d13 |
| IEDL.DBID | UNPAY |
| ISSN | 0513-5710 1346-8049 |
| IngestDate | Tue Aug 19 23:42:19 EDT 2025 Thu Aug 21 18:37:45 EDT 2025 Thu May 29 07:19:25 EDT 2025 Sat May 31 02:13:06 EDT 2025 Sun Sep 07 07:20:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | mouse mammary tumor organic light-emitting diode 5-aminolevulinic acid metronomic photodynamic therapy |
| Language | English |
| License | 2025 Tottori University Medical Press. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5604-aeb5a4ed2e8f0e1ff6857f6bfe3ad94f2cb27e367f75b67287d20430e31f68d13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/yam/advpub/0/advpub_2025.05.004/_pdf |
| PMID | 40432740 |
| PQID | 3212784492 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | unpaywall_primary_10_33160_yam_2025_05_004 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12104577 proquest_miscellaneous_3212784492 pubmed_primary_40432740 medicalonline_journals_di2yonag_2025_006802_004_0114_01224557109 |
| PublicationCentury | 2000 |
| PublicationDate | 20250000 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – year: 2025 text: 20250000 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | YONAGO ACTA MEDICA |
| PublicationTitleAlternate | Yonago Acta Med |
| PublicationYear | 2025 |
| Publisher | Tottori University Medical Press YAM |
| Publisher_xml | – name: Tottori University Medical Press – name: YAM |
| SSID | ssj0043506 ssib002483309 ssib023157403 ssib002483305 |
| Score | 2.3066547 |
| Snippet | [ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers.... Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid... |
| SourceID | unpaywall pubmedcentral proquest pubmed medicalonline |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 114 |
| SubjectTerms | Original |
| Title | 5-Aminolevulinic Acid-Mediated Metronomic Photodynamic Therapy for Mouse Mammary Tumors |
| URI | http://mol.medicalonline.jp/en/journal/download?GoodsID=di2yonag/2025/006802/004&name=0114-0122e https://www.ncbi.nlm.nih.gov/pubmed/40432740 https://www.proquest.com/docview/3212784492 https://pubmed.ncbi.nlm.nih.gov/PMC12104577 https://www.jstage.jst.go.jp/article/yam/advpub/0/advpub_2025.05.004/_pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 68 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1346-8049 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0043506 issn: 0513-5710 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1346-8049 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0043506 issn: 0513-5710 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: Open access medical journals (GFMER) customDbUrl: eissn: 1346-8049 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0043506 issn: 0513-5710 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1346-8049 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0043506 issn: 0513-5710 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBZbCrswdusu3qV4sKeBHMeSLOdtYayUgUsfEtY9CVmXNFlihybuyH79jiQ3NNteBnuyhSUh6RzJ39HR-YTQe0O05UoVmBJDMOWpwhUgXVwwncNSqGzhebbL0_xkQr-cs_OOUmjdHaucAy6aGvdIpk0yX_W7Qexv5bIv9RU0FCz58CLAeGeeezOlfbHS9jY6yBnA8h46mJyejb65lZgNCGY8MBMQ6gh46TC4LAkZ5KmrN7lRz330YBm8JIGt4m_g888zlHfbeiW3P-RiceMHdfwIza-7Fs6lfE_aTZWon7-xPv6Xvj9GDzsYG49CsSfolqmfojtl56g_RF8ZHi1ndbMwV62PvYxHaqZx6S8GMToujduCdxHR8dlFs2n0tpYuMQ4kBzFA6bhs2rWJS-mj6-Jxu2wu18_Q5Pjz-NMJ7u5wwAqwFMXSVExSozNT2NQMrM0Lxm1eWUOkHlKbqSrjhuTcclblHOw37aJ1U0MGkFUPyHPUq5vavESxkpkiDj4BrKCAQ2SqSAFolBtTVVaSCH3cE5voZuNa6Fm2Bbtm6gdM-OtGMnhQ4axB4Z2LzOnHMELvriUtYJo534msDfRWEMeEX1A6zCL0IkherAIfiHAERWDcpxEq9nRil8FReO9_qWcXnsrb0bdRxnmEPuzUZ1cM7DOvnwJk3zXdtZ6--pfMr9E9lwq7Rm9Qb3PZmreAozbVkd_aOurmyS_pJhyj |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBZbCrswdm_n3fBgTwM5jiVZztvCWCkDlz4krHsSsi5pssQOTdyR_fodSW5otr0M9mQLS0LSOZK_o6PzCaH3hmjLlSowJYZgylOFK0C6uGA6h6VQ2cLzbJen-cmEfjln5x2l0Lo7VjkHXDQ17pFMm2S-6neD2N_KZV_qK2goWPLhRYDxzjz3Zkr7YqXtbXSQM4DlPXQwOT0bfXMrMRsQzHhgJiDUEfDSYXBZEjLIU1dvcqOe--jBMnhJAlvF38Dnn2co77b1Sm5_yMXixg_q-BGaX3ctnEv5nrSbKlE_f2N9_C99f4wedjA2HoViT9AtUz9Fd8rOUf8MfWV4tJzVzcJctT72Mh6pmcalvxjE6Lg0bgveRUTHZxfNptHbWrrEOJAcxACl47Jp1yYupY-ui8ftsrlcP0eT48_jTye4u8MBK8BSFEtTMUmNzkxhUzOwNi8Yt3llDZF6SG2mqowbknPLWZVzsN-0i9ZNDRlAVj0gh6hXN7V5gWIlM0UcfAJYQQGHyFSRAtAoN6aqrCQR-rgnNtHNxrXQs2wLds3UD5jw141k8KDCWYPCOxeZ049hhN5dS1rANHO-E1kb6K0gjgm_oHSYRegoSF6sAh-IcARFYNynESr2dGKXwVF473-pZxeeytvRt1HGeYQ-7NRnVwzsM6-fAmTfNd21nr78l8yv0D2XCrtGr1Fvc9maN4CjNtXbbob8AkKxG5M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=5-Aminolevulinic+Acid-Mediated+Metronomic+Photodynamic+Therapy+for+Mouse+Mammary+Tumors&rft.jtitle=Yonago+acta+medica&rft.au=Osaki%2C+Tomohiro&rft.au=Shiomi%2C+Hikaru&rft.au=Nishimura%2C+Takahiro&rft.au=Sakanoue%2C+Kei&rft.date=2025&rft.pub=YAM&rft.issn=0513-5710&rft.eissn=1346-8049&rft.volume=68&rft.issue=2&rft.spage=114&rft.epage=122&rft_id=info:doi/10.33160%2Fyam.2025.05.004&rft.externalDocID=PMC12104577 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5710&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5710&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5710&client=summon |